Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.09
NAS:ENDP's Cash to Debt is ranked lower than
53% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. NAS:ENDP: 0.09 )
NAS:ENDP' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.09

Equity to Asset 0.22
NAS:ENDP's Equity to Asset is ranked lower than
51% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. NAS:ENDP: 0.22 )
NAS:ENDP' s 10-Year Equity to Asset Range
Min: 0.08   Max: 0.76
Current: 0.22

0.08
0.76
F-Score: 4
Z-Score: 1.06
M-Score: -2.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -31.17
NAS:ENDP's Operating margin (%) is ranked higher than
54% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. NAS:ENDP: -31.17 )
NAS:ENDP' s 10-Year Operating margin (%) Range
Min: -31.17   Max: 38.19
Current: -31.17

-31.17
38.19
Net-margin (%) -25.07
NAS:ENDP's Net-margin (%) is ranked higher than
54% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. NAS:ENDP: -25.07 )
NAS:ENDP' s 10-Year Net-margin (%) Range
Min: -79.44   Max: 24.67
Current: -25.07

-79.44
24.67
ROE (%) -32.30
NAS:ENDP's ROE (%) is ranked higher than
54% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. NAS:ENDP: -32.30 )
NAS:ENDP' s 10-Year ROE (%) Range
Min: -113.34   Max: 26.98
Current: -32.3

-113.34
26.98
ROA (%) -7.58
NAS:ENDP's ROA (%) is ranked higher than
58% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. NAS:ENDP: -7.58 )
NAS:ENDP' s 10-Year ROA (%) Range
Min: -39.34   Max: 17.45
Current: -7.58

-39.34
17.45
ROC (Joel Greenblatt) (%) -138.67
NAS:ENDP's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. NAS:ENDP: -138.67 )
NAS:ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -116.32   Max: 753.26
Current: -138.67

-116.32
753.26
Revenue Growth (3Y)(%) -4.60
NAS:ENDP's Revenue Growth (3Y)(%) is ranked higher than
59% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. NAS:ENDP: -4.60 )
NAS:ENDP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.6   Max: 30.3
Current: -4.6

-4.6
30.3
» NAS:ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ENDP Guru Trades in Q1 2014

Paul Tudor Jones 3,506 sh (New)
Julian Robertson 22,800 sh (New)
Larry Robbins 1,964,201 sh (New)
George Soros 198,503 sh (New)
Louis Moore Bacon 5,602 sh (New)
Steven Cohen 271,917 sh (+1456.75%)
Wallace Weitz 500,920 sh (+12.33%)
John Griffin 676,600 sh (unchged)
John Griffin 8,000,000 sh (unchged)
John Griffin 8,000,000 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
David Dreman Sold Out
Joel Greenblatt Sold Out
Stanley Druckenmiller Sold Out
Steve Mandel 4,178,703 sh (-3.72%)
Mario Gabelli 30,550 sh (-8.40%)
Jana Partners 2,563,215 sh (-11.53%)
Jim Simons 49,493 sh (-95.08%)
» More
Q2 2014

ENDP Guru Trades in Q2 2014

Joel Greenblatt 88,697 sh (New)
Chuck Royce 1,300 sh (New)
Paul Tudor Jones 177,373 sh (+4959.13%)
Louis Moore Bacon 15,334 sh (+173.72%)
Larry Robbins 3,930,472 sh (+100.11%)
Wallace Weitz 876,670 sh (+75.01%)
Jana Partners 3,199,017 sh (+24.80%)
John Griffin 6,766 sh (unchged)
Julian Robertson 22,800 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Steve Mandel Sold Out
John Griffin 6,815,000 sh (-14.81%)
Mario Gabelli 23,900 sh (-21.77%)
» More
Q3 2014

ENDP Guru Trades in Q3 2014

Larry Robbins 5,658,326 sh (+43.96%)
John Griffin 676,600 sh (unchged)
Louis Moore Bacon Sold Out
Jana Partners Sold Out
Chuck Royce Sold Out
Mario Gabelli 22,900 sh (-4.18%)
Julian Robertson 20,300 sh (-10.96%)
John Griffin 5,698,528 sh (-16.38%)
Wallace Weitz 721,950 sh (-17.65%)
Joel Greenblatt 13,716 sh (-84.54%)
Paul Tudor Jones 19,281 sh (-89.13%)
» More
Q4 2014

ENDP Guru Trades in Q4 2014

George Soros 1,748,729 sh (New)
Pioneer Investments 389,510 sh (New)
RS Investment Management 351,943 sh (New)
Larry Robbins 6,851,326 sh (+21.08%)
Wallace Weitz 767,530 sh (+6.31%)
John Griffin 676,600 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Julian Robertson Sold Out
Mario Gabelli 19,900 sh (-13.10%)
John Griffin 4,409,000 sh (-22.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Endo International PLC

Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector
During the campaigns in the recently concluded midterm elections, incumbent Democrats were reluctant to speak of Obamacare, almost as hesitant as they were to be seen with the president, on the campaign trail. Read more...

Ratios

vs
industry
vs
history
Forward P/E 17.92
ENDP's Forward P/E is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. ENDP: 17.92 )
N/A
P/B 5.83
ENDP's P/B is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. ENDP: 5.83 )
ENDP' s 10-Year P/B Range
Min: 1.48   Max: 17.5
Current: 5.83

1.48
17.5
P/S 4.68
ENDP's P/S is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. ENDP: 4.68 )
ENDP' s 10-Year P/S Range
Min: 1.03   Max: 6.1
Current: 4.68

1.03
6.1
PFCF 72.61
ENDP's PFCF is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. ENDP: 72.61 )
ENDP' s 10-Year PFCF Range
Min: 4.6   Max: 264.07
Current: 72.61

4.6
264.07
POCF 49.75
ENDP's POCF is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. ENDP: 49.75 )
ENDP' s 10-Year POCF Range
Min: 3.96   Max: 90.18
Current: 49.75

3.96
90.18
EV-to-EBIT -22.26
ENDP's EV-to-EBIT is ranked higher than
58% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. ENDP: -22.26 )
ENDP' s 10-Year EV-to-EBIT Range
Min: -29.3   Max: 26.5
Current: -22.26

-29.3
26.5
Current Ratio 1.07
ENDP's Current Ratio is ranked higher than
52% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. ENDP: 1.07 )
ENDP' s 10-Year Current Ratio Range
Min: 1.07   Max: 3.06
Current: 1.07

1.07
3.06
Quick Ratio 0.91
ENDP's Quick Ratio is ranked higher than
56% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ENDP: 0.91 )
ENDP' s 10-Year Quick Ratio Range
Min: 0.91   Max: 2.88
Current: 0.91

0.91
2.88
Days Inventory 116.84
ENDP's Days Inventory is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. ENDP: 116.84 )
ENDP' s 10-Year Days Inventory Range
Min: 66.62   Max: 157.75
Current: 116.84

66.62
157.75
Days Sales Outstanding 156.64
ENDP's Days Sales Outstanding is ranked higher than
61% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. ENDP: 156.64 )
ENDP' s 10-Year Days Sales Outstanding Range
Min: 62.07   Max: 164.01
Current: 156.64

62.07
164.01

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -4.50
ENDP's Earnings Yield (Greenblatt) is ranked higher than
54% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ENDP: -4.50 )
ENDP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.8   Max: 25.4
Current: -4.5

3.8
25.4
Forward Rate of Return (Yacktman) 17.97
ENDP's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.09 vs. ENDP: 17.97 )
ENDP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 63.3
Current: 17.97

3.3
63.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EO7.Germany, ENL.Canada,
Endo International PLC was formed on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.
» More Articles for NAS:ENDP

Headlines

Articles On GuruFocus.com
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
George Soros' Top New Holdings Feb 18 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
Pioneer Investments Purchases Time Warner Cable, Kohl's in Q4 Feb 10 2015 
Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector Dec 01 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 

More From Other Websites
Can Boston Scientific Keep Its Turnaround Gains Going? Mar 30 2015
Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A Mar 28 2015
Point72 Reduces Its Stake in Valeant Pharmaceuticals Mar 27 2015
Two Future Leaders of Specialty Pharma Mar 23 2015
Actavis' Wide-Moat Transformation Offers Shareholder Rewards Mar 23 2015
[$$] Proceedings: News Digest Mar 22 2015
Dovish Fed stance lifts US stocks near records Mar 20 2015
Salix execs – including two that resigned – to receive $78M in golden parachutes Mar 19 2015
Valeant (VRX) Prices Shares to Finance Salix Acquisition - Analyst Blog Mar 18 2015
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals,... Mar 18 2015
Endo Finance Co. -- Moody's confirms Endo's Ba3 ratings; outlook stable Mar 17 2015
Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog Mar 17 2015
Valeant Bonds Trade Higher, Despite Skepticism Mar 17 2015
Valeant Bumps Its Offer to $173 to Seal the Salix Deal Mar 17 2015
For health-care stocks, buy what executives are buying Mar 17 2015
PRESS DIGEST - Wall Street Journal - March 17 Mar 17 2015
Valeant Wins Battle for Salix Pharmaceuticals Mar 16 2015
Endo May Hunt Smaller Prey After Losing Out on Salix: Real M&A Mar 16 2015
After-hours buzz: Jumei, American Air & more Mar 16 2015
The Salix-Endo Proposal: Basics of the Transaction Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK